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Abstract 1 
 2 
Objective: Angiogenesis has been demonstrated to modulate adipogenesis and obesity. This study 3 
was undertaken to determine whether the botanical drug ALS-L1023 (ALS), which exhibits 4 
antiangiogenic activity, can regulate adipose tissue growth in high-fat-diet-induced obese mice. 5 
Materials and Methods: The effects of ALS on angiogenesis and extracellular matrix remodeling 6 
were measured using in vitro assays. The effects of ALS on adipose tissue growth was investigated in 7 
nutritionally obese mice.  8 
Results: ALS inhibited angiogenesis in a concentration-dependent manner in the tube formation assay 9 
and the VEGF-induced proliferation assay using human umbilical vein endothelial cells. ALS also 10 
suppressed matrix metalloproteinase (MMP) activity in vitro. ALS administration to high-fat-diet-11 
induced obese mice significantly reduced body weight gain, adipose tissue mass, and adipocyte size 12 
compared with the findings in the controls. ALS treatment decreased blood vessel density and MMP 13 
activity in adipose tissues. ALS reduced the mRNA levels of angiogenic factors (VEGFs and FGF-2) 14 
and MMPs (MMP-2 and MMP-9), whereas it increased the mRNA levels of angiogenic inhibitors 15 
(TSP-1 and TIMPs) in adipose tissues.  16 
Conclusion: These results suggest that in vivo and in vitro treatment with ALS, which has 17 
antiangiogenic and MMP inhibitory activities, reduces adipose tissue mass in nutritionally induced 18 
obese mice, providing evidence that adipose tissue growth can be regulated by angiogenesis inhibitors.  19 
 20 
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Introduction 1 
 2 
Obesity is characterized by increased adipose tissue mass that results from both increased fat cell 3 
number (hyperplasia) and increased fat cell size (hypertrophy).1 The development of obesity is 4 
associated with extensive modifications of adipose tissue involving adipogenesis, angiogenesis, and 5 
extracellular matrix (ECM) remodeling.2 Similar to neoplastic tissue, adipose tissue is highly 6 
vascularized, and each adipocyte is nourished by an extensive capillary network.2-4 Extensive changes 7 
in ECM remodeling have also been observed during adipose tissue growth.6 The matrix 8 
metalloproteinase (MMP) system plays important roles in the development of adipose tissue and 9 
microvessel maturation via ECM modulation.5-7 In most cases, MMPs are expressed at very low levels, 10 
but their expression is rapidly induced at times of active tissue remodeling associated with 11 
adipogenesis. Therefore, it is suggested that adipose tissue growth is dependent on angiogenesis and 12 
may be inhibited by angiogenesis inhibitors. 13 
Activated adipocytes produce an array of vascular growth factors, including vascular endothelial 14 
growth factor (VEGF), fibroblast growth factor (FGF), soluble VEGF receptor-2 (VEGFR2), 15 
hepatocyte growth factor, angiopoietin-2, and angiogenin. The serum concentrations of these growth 16 
factors are higher in overweight or obese individuals than in normal-weight individuals.8 In addition to 17 
secreting vascular growth factors, adipocytes release several MMPs that modulate the ECM and allow 18 
matrix-bound vascular growth factors to induce angiogenesis. Thus, angiogenesis and MMP inhibitors 19 
are in development as targeted antiobesity therapeutics.9  20 
We screened the antiangiogenic and MMP inhibitory activities of extracts of medicinal herbs and 21 
found that Melissa officinalis L.(Labiatae; lemon balm) exhibits antiangiogenic and MMP inhibitory 22 
activities.10 Melissa has been used to as a medicinal plant to treat nervousness, insomnia, 23 
gastrointestinal disorders, herpes virus infection, and Alzheimer's disease.11-16 An active fraction 24 
denominated ALS-L1023 (ALS) exhibited enhanced antiangiogenic and MMP inhibitory activities. 25 
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When high-fat-diet-induced obese mice were treated with ALS, adipose tissue mass and adipocyte 1 
size were significantly reduced in treated mice compared with that in control mice. The mRNA 2 
expression of angiogenic factors, MMPs, and their inhibitors were also modulated by ALS in obese 3 
mice. These studies suggest that antiangiogenic ALS can inhibit the growth of adipose tissue. 4 
 5 
 6 
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Materials and methods 1 
 2 
Preparation of ALS  3 
ALS was manufactured by activity-guided fractionation from the leaves of Melissa officinalis L. 4 
(Alfred Galke GmbH, Harz, Germany). The dried Melissa leaves were extracted with aqueous ethanol, 5 
and the extract was filtered and concentrated. The concentrated ethanol extract was further 6 
fractionated with ethyl acetate, after which it was concentrated and dried to obtain ALS in a dried 7 
powder form. The quality of ALS was controlled by standardization with reference compounds. ALS 8 
exhibited enhanced antiangiogenic and MMP inhibitory activities compared with that of water extract 9 
or ethanol extract of Melissa leaves. 10 
 11 
In vitro human umbilical vein endothelial cell (HUVEC) tube formation assay 12 
To perform the tube formation assay, HUVECs were purchased from Lonza (Basel, Switzerland) 13 
and cultured in M199 medium supplemented with 10% fetal bovine serum (FBS) and endothelial cell 14 
growth supplement (Sigma-Aldrich, St. Louis, MO, USA) at 50 µg/ml in a 37°C incubator with a 15 
humidified atmosphere containing 5% CO2. Two hundred microliters of Matrigel (BD Biosciences, 16 
Bedford, MA, USA) were pipetted into the wells of a 48-well plate and allowed to solidify for 1 h at 17 
37°C. HUVECs were plated on Matrigel-coated wells at a density of 4 × 104 cells/well and incubated 18 
for 16 h at 37°C with medium in the absence or presence of 25, 50, or 100 µg/ml ALS. The formation 19 
of capillary-like tubular networks was observed with an inverted microscope and photographed. The 20 
percentage of tubule area was quantified by image analysis using Image-Pro Plus (Media Cybernetics, 21 
Bethesda, MD, USA).  22 
 23 
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VEGF-induced HUVEC proliferation assay 1 
HUVECs were plated on 96-well plates at a density of 1 × 104 cells per well and incubated for 24 2 
h at 37°C with medium containing 10 ng/ml VEGF in the absence or presence of 25 or 50 µg/ml ALS 3 
dissolved in DMSO. HUVEC proliferation was measured by counting cells. After 48 h, the 4 
proliferation of HUVECs was measured by the XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-5 
tetrazolium-5-carboxanilide disodium salt) test using a Cell Proliferation Kit II (Roche, Cat. No. 6 
1465015).  7 
 8 
MMP assay 9 
MMP activities were measured on an LS50B spectrofluorometer (Perkin-Elmer, Waltham, MA, 10 
USA) using 2,4-dinitrophenyl-Pro-Leu-Gly-Met-Trp-Ser-Arg (Calbiochem, San Diego, CA, USA) as 11 
a substrate for MMP-2 and MMP-9. Recombinant human MMP-2 and MMP-9 were purchased from 12 
R&D Systems (Minneapolis, MN, USA) and used after activation with 1 mM APMA (amino-phenyl 13 
mercuric acetate) before the assay. MMP (10 nM) and substrate (1 µM) were mixed in 2 ml of 14 
reaction buffer (50 mM Tricine, pH 7.5, 10 mM CaCl2, 200 mM NaCl) in the presence or absence of 15 
ALS. Fluorescence intensity was measured at room temperature using a 280-nm excitation 16 
wavelength and a 360-nm emission wavelength. 17 
 18 
Animal study  19 
Eight-week-old male wild-type C57BL/6J mice (n=8/group) were randomly divided into four 20 
groups that exhibited uniformity in response to each treatment in the pilot study. Mice were fed for 8 21 
weeks with a low-fat diet (13% kcal fat, CJ, Incheon, Korea), a high-fat diet (45% kcal fat, Research 22 
Diets, New Brunswick, NJ, USA), or the same high-fat diet supplemented with 0.4 or 0.8% (w/w) 23 
ALS. The body weight of each animal was measured daily by a person blinded to the treatments. Food 24 
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intake was determined by estimating the amount of food consumed by the mice throughout the 1 
treatment period. After a 12-h fast on the last day of the study, the animals were sacrificed by cervical 2 
dislocation. Blood was collected from the retroorbital sinus into tubes, and serum was separated and 3 
stored at −80°C until analysis. Visceral (VSC) and subcutaneous (SC) fat pads were removed, 4 
weighed, snap-frozen, in liquid nitrogen, and stored at −80°C until use. Portions were prepared for 5 
histology. All animal experiments were approved by the Institutional Animal Care and Use 6 
Committees of Mokwon University and were conducted according to National Research Council 7 
Guidelines. 8 
 9 
Histological analysis 10 
For hematoxylin and eosin (H&E) staining, adipose tissues were fixed in 10% phosphate-11 
buffered formalin for 1 day and processed in a routine manner for paraffin sections. Tissue sections (5 12 
μm) were cut and stained with H&E for microscopic examination. To quantify adipocyte size, the 13 
H&E-stained sections were analyzed using the Image-Pro Plus analysis system. 14 
Blood vessel staining was performed using a blood vessel staining kit (Chemicon, Billerica, MA, 15 
USA). Adipose tissues were fixed in 10% phosphate-buffered formalin for 1 day and processed in a 16 
routine manner for paraffin sections. Sections (3-μm thick) were cut and irradiated in a microwave 17 
oven for epitope retrieval. Sections were incubated with a rabbit anti-von Willebrand Factor (vWF) 18 
antibody as a primary antibody, goat anti-rabbit antibody as a secondary antibody, and streptavidin-19 
alkaline phosphatase solution. A freshly prepared chromogen reagent was added to sections for the 20 
visualization of blood vessel.  21 
 22 
Zymography  23 
.Adipose tissues were weighed and extracted with 10 mM sodium phosphate buffer (pH 7.2) 24 
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containing 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium 1 
deoxycholate, and 0.2% NaN3 at 4°C. Adipose tissue extracts were mixed with zymography sample 2 
buffer (63 mM Tris HCl, 10% glycerol, 2% SDS, 0.0025% bromophenol blue, pH 6.8) without heat 3 
denaturation. The HT1080 cell culture medium was used for the molecular weight markers for MMP. 4 
Electrophoresis was performed at 125 V on 10% SDS-polyacrylamide gels containing 0.1% gelatin. 5 
After electrophoresis, the gels were incubated in renaturing buffer containing 0.25% Triton X-100 for 6 
30 min at room temperature and equilibrated in developing buffer (50 mM Tris base, 40 mM HCl, 200 7 
mM NaCl, 5 mM CaCl2, 0.2% Brij-35) for 30 min at room temperature. The gels were then incubated 8 
in developing buffer overnight at 37°C. The gels were stained with 0.1% Coomassie Blue R-250 and 9 
destained with 10% acetic acid in 40% methanol. 10 
 11 
Reverse transcription-polymerase chain reaction (RT-PCR) 12 
Total cellular RNA from retroperitoneal and inguinal adipose tissues was prepared using Trizol 13 
reagent (Gibco-BRL, Grand Island, NY, USA). After 2 μg total RNA were reverse-transcribed using 14 
Moloney murine leukemia virus reverse transcriptase and an antisense primer, cDNA was generated. 15 
Synthesized cDNA fragments were amplified by PCR in an MJ Research Thermocycler (Waltham, 16 
MA, USA). The PCR primers used for gene expression analysis are shown in Table 1. The cDNA was 17 
mixed with PCR primers, Taq DNA polymerase (Solgent, Daejon, Korea), and a deoxyribonucleotide 18 
triphosphate mixture. The reaction consisted of 30 cycles of denaturation for 1 min at 94°C, annealing 19 
for 1 min at 58°C, and elongation for 1 min at 72°C. PCR products were quantified from agarose gels 20 
using GeneGenius (Syngene, Cambridge, UK).  21 
 22 
Statistics 23 
Unless otherwise indicated, all values are expressed as mean ± standard deviation (SD). All data 24 
9 
 
were analyzed by the unpaired Student t-test to determine statistically significant differences between 1 
groups. 2 
3 
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Results 1 
 2 
Inhibition of angiogenesis by ALS 3 
When ALS was added to the cell culture at a concentration of 25, 50, or 100 µg/ml in an in vitro 4 
HUVEC tube formation assay, total tubule area and length were decreased in ALS-treated cells 5 
compared to that in control cells (Fig. 1A). The capillary-like tube formation of HUVECs was 6 
inhibited in a concentration-dependent manner, demonstrating that ALS exerts antiangiogenic effects 7 
by inhibiting the differentiation and migration of endothelial cells.  8 
Endothelial cell proliferation is considered one of the essential events of angiogenesis. VEGF 9 
plays important roles in pathogenic angiogenesis as an angiogenic stimulator by inducing endothelial 10 
cell proliferation. When ALS was added to the culture at a concentration of 25 or 50 µg/ml in VEGF-11 
induced HUVEC proliferation assays, VEGF-induced endothelial cell proliferation was inhibited by 12 
66 and 100%, respectively, compared with control cell proliferation (p<0.05; Fig. 1B). Thus, ALS 13 
exerts antiangiogenic effects by inhibiting endothelial cell proliferation. 14 
 15 
Inhibition of MMP activity by ALS 16 
MMP-2 and MMP-9 contribute to tissue remodeling by degrading the ECM in angiogenic 17 
processes as well as participate in adipocyte differentiation. The activities of MMP-2 and MMP-9 18 
were inhibited by ALS in a concentration-dependent manner. The IC50 values were 17.7±1.0 µg/ml for 19 
MMP-2 and 12.3±1.4 µg/ml for MMP-9 (Fig. 2). Thus, ALS may exert inhibitory effects on both 20 
angiogenesis and adipocyte differentiation. 21 
 22 
Effects of ALS on body weight and adipose tissue mass  23 
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To determine whether ALS reduces body weight gain and adipose tissue mass in obese mice, mice 1 
were fed a low-fat diet, a high-fat diet, or the same high-fat diet supplemented with 0.4 or 0.8% ALS 2 
for 8 weeks. After 8 weeks, the high-fat-diet-fed mice had 166% greater body weight gains compared 3 
to that of low-fat-diet-fed mice (17.0±1.49 g vs. 6.38±1.87 g, respectively, p<0.05). In contrast, mice 4 
fed a high-fat diet supplemented with 0.4 and 0.8% ALS had 70 (4.96±1.05 g) and 84% (2.72±0.60 g) 5 
lower body weights, respectively, than obese mice fed a high-fat diet alone (p<0.05; Fig. 3A). ALS 6 
was not toxic at either concentration. 7 
Adipose tissue mass was also significantly decreased by ALS treatment in high-fat-diet-fed obese 8 
mice (Fig. 3B). As shown in Fig. 3C and D, the mass of both VSC and SC fat pads in ALS-treated 9 
mice was reduced in comparison to that of high-fat-diet-fed control mice. VSC and SC adipose tissue 10 
weights were decreased by 73 and 71% after 0.8% ALS administration, respectively. Compared with 11 
high-fat-diet-fed mice, 0.8% ALS-enriched high-fat-diet-fed mice had lower VSC (1.43±0.16 g vs. 12 
0.37±0.06 g) and SC fat mass (4.24±0.73 g vs. 1.2±0.13 g). In addition, brown fat mass was decreased 13 
by 45% in 0.8% ALS-treated mice compared with that in obese mice, whereas liver, kidney, and heart 14 
weights were not changed by ALS treatment (data not shown). However, ALS treatment did not affect 15 
food consumption profiles throughout the study (Fig. 3E). 16 
 17 
Effects of ALS on adipocyte size  18 
Consistent with the effects of ALS on adipose tissue weight, the analysis of H&E-stained adipose 19 
tissue sections revealed that ALS markedly decreased the size of adipocytes. ALS at concentrations of 20 
0.4 and 0.8% decreased the average size of VSC adipocytes by 47 and 48%, respectively (Fig. 4A). 21 
The average size of adipocytes was 5571±271 μm2 in 0.4% ALS-treated mice and 5394±216 μm2 in 22 
0.8% ALS-treated mice, which were lower than that of the high-fat-diet-fed obese mice (10565±495 23 
μm2; p<0.05). ALS at concentrations of 0.4% and 0.8% also decreased the average size of SC 24 
adipocytes by 40 and 52%, respectively (Fig. 4B). The average size of adipocytes was 4475±420 μm2 25 
12 
 
in 0.4% ALS-treated mice and 3585±446 μm2 in 0.8% ALS-treated mice, which were lower than that 1 
of the high-fat-diet-fed mice (7544±1978 μm2; p<0.05).  2 
 3 
Effects of ALS on vascularization in adipose tissue  4 
To determine whether the decrease of adipose tissue mass by ALS resulted from the inhibition of 5 
angiogenesis, we studied the effects of ALS on blood vessel density in both VSC and SC adipose 6 
tissue. Staining adipose tissue sections with an antibody against vWF, an endothelial cell marker, 7 
revealed that the blood vessel density of both VSC and SC adipose tissue from ALS-treated mice was 8 
lower than that of high-fat-diet-fed control mice (Fig. 5).  9 
 10 
Effects of ALS on MMP activity in adipose tissue  11 
MMP activity in adipose tissue extracts was examined using zymography on gelatin-containing 12 
gels. Gelatin zymography revealed that proMMP-2 activity was significantly reduced in the adipose 13 
tissue from ALS-treated mice compared with that from the control group, whereas proMMP-9 levels 14 
were not detectable. The proMMP-2 activity in VSC adipose tissue was reduced by 48 and 49% after 15 
the administration of 0.4 and 0.8% ALS, respectively (Fig. 6A). Similarly, proMMP-2 activity in SC 16 
adipose tissue was also decreased by 23 and 36% after treatment with 0.4 and 0.8% ALS, respectively 17 
(Fig. 6B). 18 
 19 
Effects of ALS on mRNA expression of angiogenic factors, MMPs, and their inhibitors in adipose 20 
tissue  21 
The expression patterns of genes involved in angiogenesis were investigated in VSC and SC 22 
adipose tissues from C57BL/6J mice fed a high-fat diet. The mRNA expression of angiogenic and 23 
13 
 
antiangiogenic factors was downregulated and upregulated, respectively, in ALS-treated mice 1 
compared with those in high-fat-diet-fed obese mice. In VSC fat tissue, the mRNA levels of 2 
angiogenic factors VEGF-A, -B, -C, and -D were decreased by 45 (p<0.05), 9 (p<0.05), 17, and 16%, 3 
respectively, whereas the mRNA levels of the antiangiogenic molecule TSP-1 were increased by 41% 4 
(p<0.05) in ALS-treated mice compared with those in obese mice (p<0.05; Fig. 7A). In SC fat tissue, 5 
the mRNA expression of FGF-2, VEGF-A, -B, -C, and -D was reduced by 29 (p<0.05), 83 (p<0.05), 6 
11, 25, and 48% (p<0.05), respectively, whereas TSP-1 mRNA levels were elevated by 11% in ALS-7 
treated mice compared with those in obese mice (Fig. 7B). 8 
Similarly, MMP mRNA expression was inhibited significantly by ALS treatment. MMP-2 and 9 
MMP-9 levels were decreased by 19 (p<0.05) and 81% (p<0.05), respectively, in VSC adipose tissue 10 
and by 20 and 41% (p<0.05), respectively, in SC adipose tissue (Fig. 7A and B). In contrast, TIMP-1 11 
and TIMP-2 mRNA levels were increased by 69 (p<0.05) and 31% (p<0.05), respectively, in VSC 12 
adipose tissue and by 122 (p<0.05) and 43% (p<0.05), respectively, in SC adipose tissue from ALS-13 
treated mice compared with those in obese mice.  14 
 15 
16 
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Discussion 1 
 2 
Angiogenesis is a fundamental requirement  for embryonic development  wound healing, and 3 
female cyclical changes within the endometrium.17 However, angiogenesis is also the underlying 4 
pathological process of all major diseases of the developed world. It is a prominent feature of cancer, 5 
atherosclerosis, diabetes, rheumatoid arthritis, and proliferative retinopathy.18,19  Similarly, the growth 6 
and expansion of adipose tissue require the formation of new blood vessels to provide oxygen and 7 
nutrients to adipocytes. Recently, we demonstrated that the antiangiogenic herbal composition Ob-X 8 
reduces adipose tissue mass and suppresses obesity by inhibiting angiogenesis in nutritionally and 9 
genetically obese mice,20,21 suggesting that antiangiogenic drugs provide a novel therapeutic option 10 
for preventing and treating human obesity. In the present study, we prepared the antiangiogenic 11 
botanical drug ALS and observed its effects in obese mice. Our results demonstrated that ALS 12 
inhibited adipose tissue growth by inhibiting angiogenesis and MMP activity.  13 
We primarily examined the antiangiogenic activity of ALS by using HUVEC tube formation and 14 
VEGF-induced HUVEC proliferation assays. ALS inhibited the capillary-like tube formation of 15 
HUVECs in a concentration-dependent manner and markedly reduced VEGF-induced HUVEC 16 
proliferation, demonstrating that ALS exerts antiangiogenic effects by inhibiting the proliferation and 17 
migration of endothelial cells. Angiogenesis often precedes adipogenesis in the developing adipose 18 
tissue.2 Newly formed adipose tissue depends on continued angiogenesis for further growth.22 It has 19 
been demonstrated that different angiogenesis inhibitors significantly reduced body weight and 20 
adipose tissue mass,23 strongly indicating an inhibitory role of ALS in adipose tissue growth. 21 
In addition to angiogenesis, adipose tissue development is also known to be associated with 22 
MMPs, which play major roles in ECM remodeling. Moreover, adipocytes have to be extensively 23 
remodeled to allow the hypertrophic development observed in obesity.24 Several studies suggest that 24 
MMPs play a role in the tissue remodeling events associated with adipogenesis. MMP-2 and MMP-9 25 
15 
 
can remodel the ECM of murine and human adipocytes to facilitate the adipogenic process7,25 and 1 
regulate the bioavailability of adipocyte growth factors sequestered as inactive molecules in the 2 
matrix or blocked via interactions with their binding proteins.26 ALS markedly inhibited the activities 3 
of two major MMPs (MMP-2 and MMP-9) in a concentration-dependent manner in vitro. These 4 
results strongly suggest that ALS, which can inhibit MMP activity as well as angiogenesis, can 5 
regulate adipose tissue growth. 6 
We then treated high-fat-diet-induced obese mice with ALS. Consistent with our hypothesis that 7 
ALS can inhibit adipose tissue growth, ALS substantially reduced body weight gain and adipose 8 
tissue mass. Treatment with 0.4 and 0.8% ALS for 8 weeks decreased body weight gain by 70 and 9 
84%, respectively. Both VSC and SC adipose tissue mass were also significantly decreased by 73 and 10 
71% after ALS treatment, respectively, and this effect was higher than the 59 and 65% reductions in 11 
VSC and SC adipose tissue mass, respectively, after a 12-week administration of galardin, a broad 12 
spectrum inhibitor of MMPs.5 Our data are also supported by other results indicating that several types 13 
of angiogenesis inhibitors, such as angiostatin, endostatin, and TNP-470 and its analog CKD-732 14 
inhibit fat mass expansion in mice.23,27-29 Similar to the effects of ALS on adipose tissue mass, the 15 
average size of adipocytes in both VSC and SC adipose tissues was substantially lower in ALS-treated 16 
mice than in untreated obese mice. The size of adipocytes was lower in ALS-treated mice, compared 17 
with those in control mice. These results indicate that ALS can reduce adipose tissue mass and inhibit 18 
adipocyte hypertrophy. VSC obesity due to adipocyte hypertrophy is known to be closely associated 19 
with metabolic syndromes including insulin resistance. 30-32 Given that obesity and obesity-associated 20 
disorders are associated with pathological angiogenesis,33-35 modulating angiogenesis may be a novel 21 
therapeutic approach .27,33 22 
During ALS-induced adipose tissue loss, food intake was not changed. Similarly, it was reported 23 
that the administration of angiogenesis inhibitors, such as endostatin, to ob/ob mice resulted in weight 24 
loss without appetite changes,23 and that tolylsam, an MMP inhibitor with relative specificity for 25 
16 
 
gelatinases, reduced body and fat pad weights but did not affect food intake.36 As vessels in adipose 1 
tissue may be maintained in a relatively immature state compared with those vessels in other organs 2 
that are weight-stable, and angiogenesis inhibitors target only growing or newly formed immature 3 
vessels,22 ALS may selectively target adipose tissue and cause weight reduction. The weight loss 4 
induced by antiangiogenic ALS arose specifically from the loss of adipose tissue mass, as the weights 5 
of other organs such as the liver, kidneys, and heart were not reduced in ALS-treated obese mice. Thus, 6 
ALS can reduce adipose tissue mass by targeting only the growing adipose tissue without any side 7 
effects on weight-stable organs.   8 
Consistent with the inhibitory effects of ALS on HUVEC in vitro, blood vessel staining revealed 9 
that the blood vessel density of both VSC and SC adipose tissues was reduced in ALS-treated mice 10 
compared with that in untreated obese mice. These data are supported by our previous results 11 
indicating that the antiangiogenic herbal composition Ob-X decreased the blood vessel density of 12 
VSC adipose tissue in nutritionally obese mice.20 Our present results suggest that ALS is a very potent 13 
inhibitor of angiogenesis and controls adipose tissue growth via the regulation of angiogenesis.  14 
As angiogenesis may represent a target for treating obesity, it is important to determine the 15 
expression profiles of genes involved in angiogenesis. The growing adipose tissue contains a diversity 16 
of cell populations, which determine the expression of several angiogenic modulators. Angiogenic 17 
factors, such as VEGFs and FGF-2, promote the proliferation, differentiation, migration of endothelial 18 
cells within fat tissue, 37-39 and moreover, VEGF-A and FGF-2 synergistically induce angiogenesis.40 19 
Blockage of the VEGFR2 signaling system by a neutralizing antibody inhibits both angiogenesis and 20 
preadipocyte differentiation, suggesting that VEGFs act on endothelial cells to regulate preadipocyte 21 
differentiation.41 In addition, angiogenesis inhibitors, such as TNP-470 and VEGFR2-specific 22 
inhibitors, have been demonstrated to prevent the development of obesity in genetic mouse models 23 
and studies based on high-fat diets.23,28,41,42 In contrast, TSP-1 inhibits angiogenesis in vivo and 24 
impairs the migration and proliferation of cultured microvascular endothelial cells.43 Our RT-PCR 25 
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analysis revealed that ALS administration to obese mice decreased the mRNA expression of VEGF-A, 1 
-B, -C, and -D as well as FGF-2, whereas it increased the mRNA levels of the antiangiogenic TSP-1 2 
in both VSC and SC adipose tissues.  3 
During obesity, MMP expression is modulated in adipose tissue, and MMPs (e.g., MMP-2 and 4 
MMP-9) potentially affect adipocyte differentiation.7,44,45 High MMP-2 expression was observed in 5 
the adipose tissue of mice with nutritionally induced obesity as well as in genetically obese mice.26 6 
Adipose tissue also secretes TIMPs, which act against all MMPs. Treatment with MMP inhibitors 7 
impairs adipose tissue development in mice fed a high-fat diet.5,46 Furthermore, the secretion of MMP-8 
2 and MMP-9 increases during adipocyte differentiation in both human adipocytes and mouse 9 
preadipocyte cell lines,7,44,45 suggesting that MMP-2 and MMP-9 are important for adipocyte 10 
conversion. In this study, treating obese mice with ALS decreased MMP-2 and MMP-9 mRNA levels 11 
and increased TIMP-1 and TIMP-2 mRNA levels in both VSC and SC adipose tissues, indicating that 12 
ALS exerts a specific regulatory effect on genes involved in angiogenesis and the MMP system in 13 
adipose tissues. Our observations further indicate that the inhibition of adipose tissue growth by ALS 14 
may alter the expression of genes responsible for angiogenesis and the MMP system.  15 
Zymography of VSC and SC adipose tissue extracts revealed that ALS reduced proMMP-2 16 
activity, indicating that MMP-2 is inhibited. Conversely, proMMP-9 activity was not detectable. It is 17 
also reported that in situ zymography with gelatin-containing gels on cryosections of VSC and SC 18 
adipose tissue confirmed the lower MMP-2 and MMP-9 activities in the tissues of galardin-treated 19 
animals,5 and treatment with MMP inhibitors impairs adipose tissue development in mice fed a high-20 
fat diet.46 Indeed, MMP-2−/− mice had reduced fat mass and smaller adipocyte size in both VSC and 21 
SC fat tissue compared with that in MMP-2+/+ mice, suggesting a functional role of MMP-2 in adipose 22 
tissue growth.47 Thus, these data demonstrate that the inhibition of MMP activity by ALS may lead to 23 
reduced adipose tissue mass in obese mice. 24 
18 
 
It was reported that MMPs play important roles in angiogenesis, and MMP-2 and MMP-9 1 
activities indirectly facilitate angiogenesis48,49 whereas MMP inhibitors, both synthetic and 2 
endogenous, inhibit angiogenic responses both in vivo and in vitro.50-53 Moreover, MMP-deficient 3 
mice exhibit delayed or diminished angiogenic responses during development or in response to tumor 4 
xenograft.54 However, it was also reported that MMP-based proteolysis of the ECM proteins releases 5 
anti-angiogenic cryptic fragments such as angiostatin and endostatin,,55,56 showing that inhibiting 6 
MMP activity may decrease endogenous angiogenic inhibitors. On the other hand, studies 7 
demonstrated that MMPs have novel function of modulating adipocyte differentiation, which is 8 
independent of angiogenesis, and therefore, MMP inhibitors can block the adipocyte differentiation 9 
process.7,44,45,57 Collectively, it seems that MMPs and their inhibitors play a pivotal role in controlling 10 
adipogenesis and adipose tissue growth.  11 
In conclusion, our present findings demonstrate that ALS, which inhibits angiogenesis and MMP 12 
activity, suppresses the growth and development of adipose tissue growth in obese mice . These 13 
events may be mediated by changes in the expression of genes involved in angiogenesis, and the 14 
MMP system. Thus, antiangiogenic ALS provides a possible therapeutic approach for preventing and 15 
treating human obesity and its related disorders. 16 
17 
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Figure legends 
 1 
Figure 1. Inhibitory effects of ALS on angiogenesis. (A) HUVEC tube formation. HUVECs were 2 
plated in Matrigel-coated wells with varying amounts of ALS (25, 50, and 100 µg/ml). After 3 
incubation, capillary-like tube formation was photographed (original magnification ×100). *p<0.05 4 
compared with the control group. (B) VEGF-induced HUVEC proliferation. #p<0.05 compared with 5 
the vehicle group, *p<0.05 compared with the VEGF-treated control group. 6 
 7 
Figure 2. Inhibitory effects of ALS on MMP activity. Inhibition of MMP-2 and MMP-9 activities 8 
by ALS was measured by spectrofluorometry, and the IC50 values were determined. * p<0.05 9 
compared with the vehicle group. 10 
 11 
Figure 3. Regulation of body weight gain, adipose tissue mass, and food consumption in high-12 
fat-diet-fed obese mice. Adult male mice were fed a low-fat diet, a high-fat diet, or the same high-fat 13 
diet supplemented with 0.4 or 0.8% ALS for 8 weeks. Body weights were measured daily using a top-14 
loading balance by a person blinded to the treatments. All values are expressed as the mean ± SD. (A) 15 
Body weight gains at the end of the treatment period are significantly different between the low-fat-16 
diet group and the high-fat-diet group (#p<0.05) and between the high-fat-diet group and the groups 17 
fed a high-fat diet supplemented with 0.4 or 0.8% ALS (*p<0.05). (B) Photographs of VSC adipose 18 
tissue. At the end of the study, (C) VSC and (D) SC adipose tissue weights were measured. #p<0.05 19 
compared with the low-fat-diet group, *p<0.05 compared with the high-fat-diet group. (E) Food 20 
intake was determined by estimating the amount of food consumed by the mice throughout the 21 
treatment period. 22 
 23 
26 
 
Figure 4. Light microscopic analysis of the size of adipocytes in adipose tissue. Adult male mice 1 
were fed a low-fat diet, a high-fat diet, or the same high-fat diet supplemented with 0.4 or 0.8% ALS 2 
for 8 weeks. Representative H&E-stained sections (5-µm thick) of (A) epididymal VSC and (B) 3 
inguinal SC adipose tissues are shown (original magnification ×100). Adipocyte size in the high-fat-4 
diet plus ALS groups was smaller than that in the high-fat-diet groups. The size of adipocytes in a 5 
fixed area (1,000,000 µm2) was measured. All values are expressed as the mean ± SD. #p<0.05 6 
compared with the low-fat-diet group, *p<0.05 compared with the high-fat-diet group.   7 
 8 
Figure 5. Histological analysis of the blood vessels in adipose tissue stained with an antibody 9 
against vWF. The blood vessels of (A) epididymal VSC and (B) inguinal SC adipose tissues derived 10 
from mice fed a high-fat diet or a high-fat diet supplemented with 0.8% ALS for 8 weeks were stained 11 
and analyzed (original magnification ×100).  12 
 13 
Figure 6. Zymographic analysis of adipose tissue. Extracts from (A) epididymal VSC and (B) 14 
inguinal SC adipose tissues obtained from mice fed a high-fat diet or a high-fat diet supplemented 15 
with 0.4 and 0.8% ALS for 8 weeks were applied to a gelatin-containing gel. Gelatinolytic activity 16 
was measured by zymography.  17 
 18 
Figure 7. Effects of ALS on the mRNA expression of angiogenic factors, MMPs, and their 19 
inhibitors in (A) retroperitoneal VSC and (B) inguinal SC adipose tissues of diet-induced obese 20 
mice. Adult male mice were fed a high-fat diet or a high-fat diet supplemented with 0.8% ALS for 8 21 
weeks. Representative PCR bands from one of three independent experiments are shown.  22 
 








